Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Malignant Neoplasms
|
1641 | 0.701 | 0.440 | 11 | 61792609 | 5 prime UTR variant | G/A | snv | 0.34 | 0.26 | 0.020 | 1.000 | 2 | 2014 | 2019 | ||||
Primary malignant neoplasm
|
1374 | 0.701 | 0.440 | 11 | 61792609 | 5 prime UTR variant | G/A | snv | 0.34 | 0.26 | 0.020 | 1.000 | 2 | 2014 | 2019 | ||||
Serum albumin measurement
|
3282 | 0.701 | 0.440 | 11 | 61792609 | 5 prime UTR variant | G/A | snv | 0.34 | 0.26 | 0.700 | 1.000 | 2 | 2012 | 2013 | ||||
Breast Carcinoma
|
2793 | 0.701 | 0.440 | 11 | 61792609 | 5 prime UTR variant | G/A | snv | 0.34 | 0.26 | 0.010 | 1.000 | 1 | 2016 | 2016 | ||||
Carcinoma of lung
|
1204 | 0.701 | 0.440 | 11 | 61792609 | 5 prime UTR variant | G/A | snv | 0.34 | 0.26 | 0.010 | 1 | 2018 | 2018 | |||||
Childhood Acute Lymphoblastic Leukemia
|
261 | 0.701 | 0.440 | 11 | 61792609 | 5 prime UTR variant | G/A | snv | 0.34 | 0.26 | 0.010 | 1.000 | 1 | 2016 | 2016 | ||||
Childhood Kidney Wilms Tumor
|
36 | 0.701 | 0.440 | 11 | 61792609 | 5 prime UTR variant | G/A | snv | 0.34 | 0.26 | 0.010 | 1.000 | 1 | 2018 | 2018 | ||||
Childhood Leukemia
|
140 | 0.701 | 0.440 | 11 | 61792609 | 5 prime UTR variant | G/A | snv | 0.34 | 0.26 | 0.010 | 1 | 2016 | 2016 | |||||
Endometriosis
|
274 | 0.701 | 0.440 | 11 | 61792609 | 5 prime UTR variant | G/A | snv | 0.34 | 0.26 | 0.010 | 1.000 | 1 | 2018 | 2018 | ||||
Esophageal carcinoma
|
272 | 0.701 | 0.440 | 11 | 61792609 | 5 prime UTR variant | G/A | snv | 0.34 | 0.26 | 0.010 | 1.000 | 1 | 2017 | 2017 | ||||
Esophageal Neoplasms
|
270 | 0.701 | 0.440 | 11 | 61792609 | 5 prime UTR variant | G/A | snv | 0.34 | 0.26 | 0.010 | 1.000 | 1 | 2017 | 2017 | ||||
Fuchs Endothelial Dystrophy
|
32 | 0.701 | 0.440 | 11 | 61792609 | 5 prime UTR variant | G/A | snv | 0.34 | 0.26 | 0.010 | 1 | 2018 | 2018 | |||||
leukemia
|
144 | 0.701 | 0.440 | 11 | 61792609 | 5 prime UTR variant | G/A | snv | 0.34 | 0.26 | 0.010 | 1 | 2016 | 2016 | |||||
Malignant neoplasm of breast
|
3417 | 0.701 | 0.440 | 11 | 61792609 | 5 prime UTR variant | G/A | snv | 0.34 | 0.26 | 0.010 | 1.000 | 1 | 2016 | 2016 | ||||
Malignant neoplasm of esophagus
|
214 | 0.701 | 0.440 | 11 | 61792609 | 5 prime UTR variant | G/A | snv | 0.34 | 0.26 | 0.010 | 1.000 | 1 | 2017 | 2017 | ||||
Malignant neoplasm of lung
|
1142 | 0.701 | 0.440 | 11 | 61792609 | 5 prime UTR variant | G/A | snv | 0.34 | 0.26 | 0.010 | 1 | 2018 | 2018 | |||||
Nephroblastoma
|
125 | 0.701 | 0.440 | 11 | 61792609 | 5 prime UTR variant | G/A | snv | 0.34 | 0.26 | 0.010 | 1.000 | 1 | 2018 | 2018 | ||||
Phospholipid measurement
|
306 | 0.701 | 0.440 | 11 | 61792609 | 5 prime UTR variant | G/A | snv | 0.34 | 0.26 | 0.700 | 1.000 | 1 | 2011 | 2011 | ||||
Primary malignant neoplasm of lung
|
981 | 0.701 | 0.440 | 11 | 61792609 | 5 prime UTR variant | G/A | snv | 0.34 | 0.26 | 0.010 | 1 | 2018 | 2018 | |||||
Secondary malignant neoplasm of lymph node
|
188 | 0.701 | 0.440 | 11 | 61792609 | 5 prime UTR variant | G/A | snv | 0.34 | 0.26 | 0.010 | 1.000 | 1 | 2016 | 2016 | ||||
Squamous cell carcinoma of esophagus
|
329 | 0.701 | 0.440 | 11 | 61792609 | 5 prime UTR variant | G/A | snv | 0.34 | 0.26 | 0.010 | 1.000 | 1 | 2013 | 2013 |